Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154553" target="_blank" >RIV/61989592:15110/15:33154553 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S0140-6736(15)61107-2" target="_blank" >http://dx.doi.org/10.1016/S0140-6736(15)61107-2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S0140-6736(15)61107-2" target="_blank" >10.1016/S0140-6736(15)61107-2</a>
Alternative languages
Result language
angličtina
Original language name
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
Original language description
The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocytopenia.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet Oncology
ISSN
1470-2045
e-ISSN
—
Volume of the periodical
2
Issue of the periodical within the volume
8
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
"1649-1658"
UT code for WoS article
—
EID of the result in the Scopus database
—